REVIVED-BCIS2
2022
REVascularization for Ischemic VEntricular Dysfunction — British Cardiovascular Intervention Society-2
In 700 patients with ischaemic LV dysfunction (LVEF ≤35%) and viable myocardium, PCI plus optimal medical therapy did not reduce all-cause death or HF hospitalisation compared with optimal medical therapy alone.
Result
Efficacy: Death from any cause or hospitalisation for heart failureHR 0.99 (95% CI 0.78-1.27) · P = 0.96
Below 1 favours PCI plus optimal medical therapy, above 1 favours optimal medical therapy alone.
- Absolute difference
- 0.8 points
The absolute difference is derived from the event rates.
Also reported: Neutral, with no difference in LVEF or quality of life. Median follow-up 41 months.
- Subtopic
- PCI vs OMT
- Design
- Multicentre open-label RCT
- Relevance
- Important: one of several pillars.
- Cited in
- ESC 2024 CCSACC/AHA 2023 CCD
- Source
- Perera D, et al. N Engl J Med. 2022;387(15):1351-60.doi 10.1056/NEJMoa2206606
Discussion & critique
Enrolled largely stable, minimally symptomatic patients selected for viability. Alongside STICH and ISCHEMIA, challenged the viability-guided revascularisation paradigm and downgraded routine PCI for ischaemic cardiomyopathy.